HUE030654T2 - Terápiás, kutyaféle-immunglobulinok és eljárások alkalmazásukra - Google Patents

Terápiás, kutyaféle-immunglobulinok és eljárások alkalmazásukra Download PDF

Info

Publication number
HUE030654T2
HUE030654T2 HUE12723733A HUE12723733A HUE030654T2 HU E030654 T2 HUE030654 T2 HU E030654T2 HU E12723733 A HUE12723733 A HU E12723733A HU E12723733 A HUE12723733 A HU E12723733A HU E030654 T2 HUE030654 T2 HU E030654T2
Authority
HU
Hungary
Prior art keywords
ser
val
pro
thr
leu
Prior art date
Application number
HUE12723733A
Other languages
English (en)
Inventor
David Gearing
Original Assignee
Nexvet Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44838842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE030654(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nexvet Australia Pty Ltd filed Critical Nexvet Australia Pty Ltd
Publication of HUE030654T2 publication Critical patent/HUE030654T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)

Claims (3)

r* KAPUVÁ *n\ \ï ti F l\*MÍ M.IOJU X IN'Ük F H FIO Uí ÍM*K Μ K u MA/ \m kRa Skktpi;lM:É^ pííkfek:
1 i'U) >\ fii; Xí iNiW vg·' Ί li\ksli> ’»«,"! '1 \ f í;> > k vv >'í 'fi iieiíO «ika! iS- jüV'i'S. síK'i kívánatos aéi semksnx.iteíS' neníkivánalor eífekiorfusvkuó inanx egyén, ahoi ss; etíesiavva#. féNóv fehérje vagy kiHöfeagíaens jiekéfláne knasían? doroénje tartalmazza λ $£<j H> HO:8, SEO ÍD Nikii v»8y:·$Η0·H&amp;NOtiS•«KeräfHi-msrsx'is.^ s\k%ntoun «>κ*5 &amp; ku/jx anλ»κ \<n* i**a onnsniaimikass síiíiKíiíreiuhiiiís későik aki;vai;xió {„da'A^isucana"') vNxkiodxxk·.: feig axxkxf as ellenanyag, fexxx iVhxíje vagy kkuifenoixens a ííHanngénfehe.?: kiköti,
2. Λ2 i. iyykivpom stsrirm dienern ag. fúrxx ídtséríe vagy as;svak kod ihignxxiac as sag mégha· áro2»ti iäfeakxaxxxa, aNx a kxtysíéis terápiái kesdéx.· a kniyaíéidv.·'» fájdalom vagy guilkxiN ktxek'Ssx gátiam vagy Íísökkáísuk«.
3. As I. vagy 2, Igénypr-ni saerkui oPenans-ig, fifeióc; fehétje vsg> annak kde fragnse;ne as ed inoghass-•toastnt allaiínssásra, ahoi a kmyaféfe irrápkd keseÜde íslifeií gyulladás vagy ízületi gyulladásos állápé; keselè-Sg, 4 ' ' ü'gi î. y \í>y ! ; i <, y ; ··.&amp; * xK 'yYí.'i vagy n> !- oto * · í m < < , g> ai ke ok tótpínivixn, ahol a &amp;jdakn» a KxvÁsrökböi áhé csoportból választott: nsuropátiás f^Móto, oökoíOgtai faj dalosa* ?»ás artrttlsm'l vagy feuern »rtriiisz: okozta iäitkÄi ibsáteoartHiisi^él AxxzefeggA vagy mzismäshkz ofaîs fájdalom, gyaíladássai öfezellggé vagy :fáj<M>«»:.ás viszketéssel össze függi* vagy viszketés okosN föjd&amp;Éom. ixAd i -4. sgiéï^SKtiikdiâî'ineî'yîki' s^xerim* dlesaoyag, foziôs fehérje vagy annak kötő fragmente az ott megh&amp;tátoaott altómsiSsKy aáöl aa immttmem&amp;zcr később aküvaukk· l^dwvnisrsanO efifekiorfutikcséi a kôierke/ôk alkotta esopnrtM!vlisssuktnk: ketqtletnt'tnftggd «Mmu:*tàs, eilenanv&amp;gffcggö seltközvetíteUe citotoxk»t&amp; és eiisnasfyagfüggi) »s|ias|xüög®nsais. 6. A/. S kèny|Sô«i aïsiimi «ilensat^ iSKÍéa Âéi;|<5 w&amp;.mmM kőid ftag!tt»?iRS8 aikalmazásR}, aboi ez$Êmmyà% ID fSdsè ?. As DS. ígényponink bámteix Ike &amp;2er«Rfi eHsoanyag. kV^ióa fehérje vagy annak k^iö ftagnvens.e a? Kit iVisgj'iisXi;>;>;<öit ísx-'YihinxxyT«, shoi a téianisgén k(KcikyaöKh'k; ákó csopotthfti vslaS:aföfk: csn-kín, kνκνοΥίη. aövekeJéNt iái to{s sejtfoismi &amp;ctqpov. vjnse é> a koinpiemenn-iXida:-'« iíáiínelyik kompoismstsk 8. 1. Ellenanyag, íuöös fehérja vtígy: aaecsk kdtó feagniense kniyafefe }«rápsái keutekfeáken iöriénö sikál-nsazáara, ahol kivánsioa egy cél iseg^ernnmitókk ah<ii a.r elicitany&amp;g, iúx;»:A feiferjs vagy khtéftagnvena fsahax-iáne konïkvsîa deiKinsa urîtakîi&amp;akí a S-HQ Ht NO:9, SkO Π) Ní> lU vagy SEí| Hl NO: 14 vxxíntl m&amp;iásmTt*· a?,ekv essHát, shv>l a Hehéai&amp;nc «jvnnossv-'-.aekv sík sása kwetní a.?. imn)unn'ndv>2^: · :JÜési>b» akrfellsláil «MiAfcitaÖs· sÂllâ*k| Äköv méÈmm^· fö:Ä Mië|«s vagy k^dfegmai* ællMis§è#fes® :¾¾¾ fiÁli Í|é»y{xmt'«2«átó-€Í&amp;)«ysg. &amp;x*6s íshárj? vagy aïmsk késő fragment &amp;« <>» «5cghatju«20Äv: rák vagy fertr^ö betegség késelése. í&amp; A 9:< Mny^m :sx8*ytl>^ka»ríy^ ktekA fehérje vagy ennsk Uüf> fragrncRse &amp;* <>« snegl^t&amp;ryÄ alkalmazva, Äölsa.im«a8sr«n<ii?«r k«Ä *ktiv*!6d6 („ik^va.Aiearo'l eiftksnrtoakdót * kövdkZkbdf #P' an>»gfiigg<· suites p&amp;to&amp;mtöM Ilii &amp;&amp; :|SÄie^in:«·«Μ^ΐϊίΐ?^^^:VSgy ÄÄÄ M-^&amp;i^kr' Zips, Π. Λ 11. sgénypom szeri»*} áíléssspgi föglés Miérjje vagy romák kötő ihi&amp;mens; az ok inogba-SíSAkk síksímsaSsra, ;sho* s bsksfmsiílkms saîlgfe§ MvsiksÄfeöl gH6 esoportNM váSaasum: cns>km, kemokra, «övs-feÄi ; fftier, ^ÄM:®^,ÄÄ*· komgogensav a A ! j ígéoypíxb saerimt vbvoaoyss, íóAás vagy aaoak kötő íísgmsase a?: oti moghatáRmkk AZsaZva* ÄÄ*:.^k^Ä^:aäil^a,a:^yÄ^ ^j#i· IfetaM^aM’ritaAem CÖ2, CÍM, Cö% OfcO.KiFR, VEGFR é«BBF.2.
HUE12723733A 2011-05-06 2012-05-08 Terápiás, kutyaféle-immunglobulinok és eljárások alkalmazásukra HUE030654T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161483481P 2011-05-06 2011-05-06
GBGB1114858.2A GB201114858D0 (en) 2011-08-29 2011-08-29 Anti-nerve growth factor antibodies and methods of using the same
US201161531439P 2011-09-06 2011-09-06

Publications (1)

Publication Number Publication Date
HUE030654T2 true HUE030654T2 (hu) 2017-05-29

Family

ID=44838842

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12723733A HUE030654T2 (hu) 2011-05-06 2012-05-08 Terápiás, kutyaféle-immunglobulinok és eljárások alkalmazásukra

Country Status (18)

Country Link
US (1) US10040849B2 (hu)
EP (3) EP2705057B8 (hu)
JP (2) JP5990701B2 (hu)
KR (4) KR20170070271A (hu)
CN (4) CN103732620B (hu)
AU (2) AU2012252156B2 (hu)
BR (2) BR112013028654A2 (hu)
CA (3) CA2834992C (hu)
DK (1) DK2705057T3 (hu)
ES (2) ES2704036T3 (hu)
GB (1) GB201114858D0 (hu)
HU (1) HUE030654T2 (hu)
MY (2) MY161724A (hu)
PL (1) PL2705057T3 (hu)
PT (1) PT2705057T (hu)
RU (3) RU2626527C1 (hu)
SG (5) SG10201500960TA (hu)
WO (2) WO2012153121A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
NZ587852A (en) 2002-12-24 2012-02-24 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CA3154540A1 (en) * 2013-12-20 2015-06-25 Intervet International B.V. CANINIZED ANTIBODIES
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
ES2853823T3 (es) 2014-09-30 2021-09-17 Intervet Int Bv Anticuerpos de PD-L1 que se unen a PD-L1 canino
AU2016239858B2 (en) 2015-04-02 2021-07-01 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
JP6700620B2 (ja) * 2015-05-22 2020-05-27 アステラス製薬株式会社 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
CA2995849A1 (en) * 2015-08-31 2017-03-09 The Trustees Of The University Of Pennsylvania Chimeric aav-anti-vegf for treating cancer in canines
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
WO2017119434A1 (ja) 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体
WO2017119435A1 (ja) * 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ 高親和性抗ｖｅｇｆ抗体
MX2018009955A (es) * 2016-02-18 2018-11-29 Elanco Us Inc Anticuerpo anti-cd20 quimerico canino.
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US10982002B2 (en) * 2018-03-12 2021-04-20 Zoetis Services Llc Anti-NGF antibodies and methods thereof
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
CA3167437A1 (en) 2020-02-19 2021-08-26 Verena BRAND Modified fc regions
EP4114856A4 (en) * 2020-03-03 2023-11-22 Scout Bio, Inc. ANTIGEN BINDING MOLECULES AND USES THEREOF
AU2021358987A1 (en) * 2020-10-07 2023-05-11 Zoetis Services Llc Anti-ngf antibodies and methods of use thereof
MX2023013165A (es) 2021-05-12 2023-11-30 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno que se une especificamente a rankl y ngf, y su uso medico.

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
JP2837240B2 (ja) * 1990-06-07 1998-12-14 財団法人化学及血清療法研究所 イヌ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
GB9202796D0 (en) 1992-02-11 1992-03-25 Wellcome Found Antiviral antibody
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6703360B2 (en) * 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
WO2003060080A2 (en) * 2001-12-21 2003-07-24 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
KR20050111598A (ko) * 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
JP4263951B2 (ja) * 2003-06-20 2009-05-13 財団法人日本生物科学研究所 イヌ化抗体の作成方法および使用
JP2005104936A (ja) * 2003-10-01 2005-04-21 Nippon Zenyaku Kogyo Kk イヌｔａｒｃ抗体
JP2005143436A (ja) * 2003-11-18 2005-06-09 Nippon Zenyaku Kogyo Kk イヌｍｄｃ
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
PL1732949T3 (pl) * 2004-04-07 2010-06-30 Rinat Neuroscience Corp Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
CA2577133A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
CA2694055A1 (en) * 2007-08-01 2009-02-05 Glaxo Group Limited Novel antibodies
US8722587B2 (en) * 2008-04-09 2014-05-13 The Trustees Of The University Of Pennsylvania Single chain fragment variable antibody libraries and uses thereof
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
EP2411050A4 (en) 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
JP2012521784A (ja) 2009-03-30 2012-09-20 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲーエムバーハー イヌＦｃ部分を含む融合タンパク質
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
LT3333188T (lt) 2010-08-19 2022-06-10 Zoetis Belgium S.A. Anti-ngf antikūnai ir jų panaudojimas
WO2012129330A1 (en) 2011-03-23 2012-09-27 Option Pharmaceutical, Llc Targeted cytokine for treatment of musculoskeletal diseases
SG194793A1 (en) 2011-05-06 2013-12-30 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same

Also Published As

Publication number Publication date
BR112013028523A8 (pt) 2017-12-19
SG10201500960TA (en) 2015-04-29
CA2835092A1 (en) 2012-11-15
AU2012252151A1 (en) 2013-11-14
CA2906505C (en) 2016-07-19
GB201114858D0 (en) 2011-10-12
KR20140041533A (ko) 2014-04-04
EP2705057B8 (en) 2016-09-21
EP2705057A1 (en) 2014-03-12
SG10201607259TA (en) 2016-10-28
MY161724A (en) 2017-05-15
CN103732620A (zh) 2014-04-16
RU2013154304A (ru) 2015-06-20
KR101783398B1 (ko) 2017-10-10
EP2705054A1 (en) 2014-03-12
CA2834992C (en) 2016-07-26
CN103732620B (zh) 2017-02-22
CA2835092C (en) 2020-12-08
JP2014522236A (ja) 2014-09-04
ES2601400T3 (es) 2017-02-15
KR20170070271A (ko) 2017-06-21
BR112013028654A2 (pt) 2016-11-29
JP5990701B2 (ja) 2016-09-14
SG194794A1 (en) 2013-12-30
CA2906505A1 (en) 2012-11-15
AU2012252156A1 (en) 2013-11-14
AU2012252156B2 (en) 2015-11-12
CA2834992A1 (en) 2012-11-15
RU2627191C2 (ru) 2017-08-03
CN105833268A (zh) 2016-08-10
MY161295A (en) 2017-04-15
CN105999261A (zh) 2016-10-12
BR112013028523A2 (pt) 2016-11-29
WO2012153126A1 (en) 2012-11-15
AU2012252151B2 (en) 2016-08-04
KR20140056182A (ko) 2014-05-09
RU2626527C1 (ru) 2017-07-28
EP3502137A1 (en) 2019-06-26
KR101637502B1 (ko) 2016-07-08
WO2012153121A1 (en) 2012-11-15
PL2705057T3 (pl) 2017-08-31
PT2705057T (pt) 2016-11-09
CN103732622A (zh) 2014-04-16
US20150017154A1 (en) 2015-01-15
KR20160079939A (ko) 2016-07-06
NZ617450A (en) 2015-01-30
NZ617446A (en) 2014-12-24
ES2704036T3 (es) 2019-03-13
RU2644235C2 (ru) 2018-02-08
JP2014516026A (ja) 2014-07-07
US10040849B2 (en) 2018-08-07
SG10201500954WA (en) 2015-04-29
DK2705057T3 (en) 2016-11-28
SG194796A1 (en) 2013-12-30
EP2705054B1 (en) 2018-11-14
RU2013154302A (ru) 2015-06-20
EP2705057B1 (en) 2016-08-03

Similar Documents

Publication Publication Date Title
DK2705057T3 (en) THERAPEUTIC immunoglobulins FOR DOGS AND METHODS OF USE THEREOF
US9580496B2 (en) Therapeutic canine immunoglobulins and methods of using same
JP6526089B2 (ja) 抗神経成長因子抗体ならびにそれを調製および使用する方法
AU2012252152B2 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
NZ617450B2 (en) Therapeutic canine immunoglobulins and methods of using the same
GB2528811A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same